This work suggests a tailored immunotherapeutic strategy to regulate TAM-mediated immune reactions in breast cancer subtypes by epigenetically adjusting the expression of CD80 and MSLN by modifying MALAT-1 and HOTAIR. This evidence concerns the gene MSLN and breast carcinoma.